Deborah J. Wong, MD, PhD
Accepting new patients

Deborah J. Wong, MD, PhD

  • Head and Neck Medical Oncology|
  • Hematology Oncology
Average rating: 4.9
| 451 ratings
Westwood Cancer Care | 100 Medical Plaza, Suite 550, Los Angeles, CA 90095


  • PhD, Biological Sciences, University of California, Irvine, 2005
  • MD, University of California, Irvine, 2006
  • Internal Medicine Residency, University of California, Los Angeles, 2006-2009
  • Chief Resident, Medicine, University of California, Los Angeles, 2009-2010
  • Fellow, Hematology-Oncology, University of California, Los Angeles, 2010-2013
  • Chief Fellow, Hematology-Oncology, University of California, Los Angeles, 2012-2013




Medical Board Certifications

Medical Oncology, American Board of Internal Medicine, 2013
Hematology, American Board of Internal Medicine, 2013
Internal Medicine, American Board of Internal Medicine, 2009


Hematology & Medical Oncology, UCLA School of Medicine, 2013


Internal Medicine, UCLA School of Medicine, 2009


Internal Medicine, UCLA School of Medicine, 2007


MD, UC Irvine School of Medicine, 2006
PhD, UC Irvine School of Medicine, 2005

Hospital Affiliations

Ronald Reagan UCLA Medical Center

UCLA Santa Monica Medical Center



Clinical and Research Interests: Head and Neck, Lung


  1. Wong, D.L., Rao, A.,  Avramis, E., Matsunaga, D.R , Komatsubara, K.M., Chodon, T. , Koya, R.C., Ribas, A.  and Comin-Anduix, B.  Detrimental Effects of a Histone Deacetylase Inhibitor on Human Lymphocytes.  Cancer Immunol Res, 2014, May 2014 2; 459.
  2. Atefi, M., Avramis, E., Lassen, A., Wong, D.J., Robert, L., Foulad, D., Cerniglia, M., Titz, B., Chodon, T., Graeber, T.G., Comin-Anduix, B., Ribas, A., Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma. Clinical Cancer Research. 2014, May 8. PMID: 24812408.
  3. Wong DJ, Robert L, Atefi MS, Lassen A, Avarappatt G, Cerniglia M, Avramis E, Tsoi J, Foulad D, Graeber TG, Comin-Anduix B, Samatar A, Lo RS, Ribas A. Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma. Mol Cancer. 2014 Aug 20;13:194. PMID: 25142146.
  4. Atefi, M.S., Titz, B., Avramis, E., Ng, C., Wong, D.J.L., Lassen, A., Cerniglia, M., Escuin-Ordinas, H., Foulad, D., Comin-Anduix, B., Graeber, T., and Ribas, A.  Combination of Pan-RAF and MEK inhibitors in NRAS mutant melanoma cell lines. Mol Cancer. 2015 Feb 3;14:27. PMID: 25645078
  5. Warner WA, Wong DJ, Palma-Diaz F, Shibuya TY, Momand J. Clinicopathological and Targeted Exome Gene Features of a Patient with Metastatic Acinic Cell Carcinoma of the Parotid Gland Harboring an ARID2 Nonsense Mutation and CDKN2A/B Deletion. Case Rep Oncol Med. 2015;2015:  PMID:  26634163
  6. Hu, S.B. Wong, D.J.L., Anath, A., Li, N., and Deng, J.C.  Prediction of Clinical Deterioration in Hospitalized Adult Patients with Hematologic Malignancies Using a Neural Network Model.  PLOS One, 2016 Aug 17;11(8). PMID: 27532679
  7. Naing A, Papadopoulos KP, Autio KA, Ott PA, Patel MR, Wong DJ, Falchook GS, Pant S, Whiteside M, Rasco DR, Mumm JB, Chan IH, Bendell JC, Bauer TM, Colen RR, Hong DS, Van Vlasselaer P, Tannir NM, Oft M, Infante JR.  Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors.  J Clin Oncol. 2016 Aug 15. PMID: 27528724.
  8. Chen AM, Felix C, Wang PC, Hsu S, Basehart V, Garst J, Beron P, Wong D, Rosove MH, Rao S, Melanson H, Kim E, Palmer D, Qi L, Kelly K, Steinberg ML, Kupelian PA, Daly ME.  Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study.  Lancet Oncol. 2017 Apr 20. pii: S1470-2045(17)30246-2. PMID:  28434660.
  9. Gulley JL, Rajan A, Spigel DR, Iannotti N, Chandler J, Wong DJL, Leach J, Edenfield WJ, Wang D, Grote HJ, Heydebreck AV, Chin K, Cuillerot JM, Kelly K.  Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial.  Lancet Oncol. 2017 May;18(5):599-610.  PMID:  28373005.
  10. Spiegel ML, Goldman JW, Wolf BR, Nameth DJ, Grogan TR, Lisberg AE, Wong DJL, Ledezma BA, Mendenhall MA, Genshaft SJ, Gutierrez AJ, Abtin F, Wallace WD, Adame CR, McKenzie JR, Abarca PA, Li AJ, Strunck JL, Famenini S, Carroll JM, Tucker DA, Sauer LM, Moghadam NM, Elashoff DA, Abaya CD, Brennan MB, Garon EB.  Non-small cell lung cancer clinical trials requiring biopsies with biomarker-specific results for enrollment provide unique challenges. Cancer. 2017 Dec 15;123(24):4800-4807.  PMID: 29125624.
  11. Hegde JV, Shaverdian N, Daly ME, Felix C, Wong DL, Rosove MH, Garst JH, Wang PC, Veruttipong D, Rao S, Fragoso RC, Riess JW, Steinberg ML, Chen AM.  Patient-reported quality-of-life outcomes after de-escalated chemoradiation for human papillomavirus-positive oropharyngeal carcinoma: Findings from a phase 2 trial. Cancer. 2017 Oct 17. PMID: 29044458
  12. Sullivan RJ, Infante JR, Janku F, Wong DJL, Sosman JA, Keedy V, Patel MR, Shapiro GI, Mier JW, Tolcher AW, Wang-Gillam A, Sznol M, Flaherty K, Buchbinder E, Carvajal RD, Varghese AM, Lacouture ME, Ribas A, Patel SP, DeCerescenzo GA, Emery CM, Groover AL, Saha S, Varterasian M, Welsch DJ, Hyman DM, Li BT.  First-in-class ERK1/2 inhibitor Ulixertinib (BVD-523) in patients with MAPK mutant advanced solid tumors: Results of a phase I dose escalation and expansion study.  Cancer Discov. 2018 Feb;8(2):184-195. doi: 10.1158/2159-8290.CD-17-1119. Epub 2017 Dec 15.  PMID: 29247021.
  13. Atkins M, Hodi FS, Thompson J, McDermott D, Hwu W, Lawrence D, Dawson N, Wong D, Bhatia S, JamesM, Jain L, Robey S, Shu X, Homet Moreno B, Perini R, Choueiri T, and Ribas A.  Pembrolizumab plus pegylated interferon alfa-2b or ipilimumab for advanced melanoma or renal cell carcinoma: dose-finding results from the phase 1b KEYNOTE-029 study.   Clin Cancer Res. 2018 Apr 15;24(8):1805-1815. doi: 10.1158/1078-0432.CCR-17-3436. Epub 2018 Jan 22. PMID 29358500
  14. Kelly K, Infante JR, Taylor MH, Patel MR, Wong DJ, Iannotti N, Mehnert JM, Loos AH, Koch H, Speit I, Gulley JL.  Safety profile of avelumab in patients with advanced solid tumors: a pooled analysis of data from the phase 1 JAVELIN Solid Tumor and phase 2 JAVELIN Merkel 200 clinical trials.  Cancer 2018 May 1;124(9):2010-2017. doi: 10.1002/cncr.31293. Epub 2018 Feb 22.PMID 29469949
  15. Tsoi J, Robert L, Paraiso K, Galvan C, Sheu KM, Lay J, Wong DJL, Atefi M, Shirazi R, Wang X, Braas D, Grasso CS, Palaskas N, Ribas A, Graeber TG.  Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress. Cancer Cell. 2018 May 14;33(5):890-904.e5. doi: 10.1016/j.ccell.2018.03.017. Epub 2018 Apr 12.PMID 29657129.
  16. Ribas A, Medina T, Kummar S, Amin A, Kalbasi A, Drabick JJ, Barve M, Daniels GA, Wong DJ, Schmidt EV, Candia AF, Coffman RL, Leung ACF, Janssen RS.  SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study.  Cancer Discov. 2018 Oct;8(10):1250-1257. doi: 10.1158/2159-8290.CD-18-0280. Epub 2018 Aug 28. PMID  30154193.

See more publications.


  • Aetna
  • Anthem Blue Cross
  • Blue Shield of California
  • Centivo
  • Cigna
  • First Health
  • Health Net of California
  • Interplan (part of HealthSmart)
  • L.A. Care
  • MultiPlan
  • UFCM Health System
  • Prime Health Services
  • Private Healthcare Systems (PHCS)
  • UnitedHealthcare

The list of health care plans above may not be comprehensive and could change. 
Please contact your benefits coordinator or health insurance company directly to verify coverage.

Visit our health insurance information page for more details.